Recent discussions on X about Entera Bio Ltd. (ENTX) have centered around the company's latest regulatory milestone with the FDA. Many users are highlighting the agency’s agreement to support a New Drug Application for EB613 using bone mineral density as the primary endpoint in its Phase 3 study, a development that has sparked a notable uptick in attention. This news, reported widely on financial platforms, has fueled conversations about the potential impact on the stock’s trajectory.
The buzz on X also includes anticipation for upcoming Phase 2 data expected in the third quarter, with some users speculating on the biotech’s future growth in the osteoporosis treatment market. Posts reflect a mix of optimism about recent gains and cautious curiosity regarding long-term outcomes. This development has kept the ticker active in online financial circles, drawing interest from investors tracking small-cap biotech stocks.
Note: This discussion summary was generated from an AI condensation of post data.
Entera Bio Ltd. Hedge Fund Activity
We have seen 8 institutional investors add shares of Entera Bio Ltd. stock to their portfolio, and 4 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. added 2,697,236 shares (+inf%) to their portfolio in Q1 2025, for an estimated $4,585,301
- PERIGON WEALTH MANAGEMENT, LLC removed 145,843 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $277,101
- SCHONFELD STRATEGIC ADVISORS LLC removed 33,155 shares (-5.2%) from their portfolio in Q1 2025, for an estimated $56,363
- PARKMAN HEALTHCARE PARTNERS LLC added 25,900 shares (+6.3%) to their portfolio in Q1 2025, for an estimated $44,030
- BANK OF AMERICA CORP /DE/ added 22,557 shares (+267.6%) to their portfolio in Q1 2025, for an estimated $38,346
- NORTHERN TRUST CORP removed 13,652 shares (-6.4%) from their portfolio in Q1 2025, for an estimated $23,208
- TWO SIGMA SECURITIES, LLC added 12,554 shares (+inf%) to their portfolio in Q1 2025, for an estimated $21,341
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Entera Bio Ltd. Analyst Ratings
Wall Street analysts have issued reports on $ENTX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 03/18/2025
To track analyst ratings and price targets for Entera Bio Ltd., check out Quiver Quantitative's $ENTX forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
